PLANEGG-MARTINSRIED, Germany -- 4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialisation of resminostat in Japan.
4SC will receive an upfront payment from Yakult Honsha of EUR6 million and up to EUR127 million payable upon achieving specified milestones including clinical and regulatory events in Japan. In addition to milestone payments Yakult will pay 4SC double-digit royalties linked to product sales of resminostat, which will also include the API costs. 4SC will be the exclusive supplier of resminostat to Yakult Honsha. Yakult Honsha will be responsible for all development and clinical requirements in Japan for resminostat in hepatocellular carcinoma, colorectal cancer and other chosen oncology indications.
Information and Explaination of the Issuer to this News:
Telephone Conference
4SC will host a telephone conference at 3:00 pm CET (9:00 am EST) today to inform about the agreement with Yakult Honsha.
To participate in the telephone conference, please use the following data:
Date: 14 April 2011 Time: 3:00 pm CET (9:00 am EST) Dial-in numbers: 0800 10 12 072 (Germany) 0800-358-0886 (UK) 1-877-941-2930 (USA) +49 (0) 6958 999 0804 (other countries)
Conference ID: 4433039
Approximately two hours after the live telephone conference, an audio replay of the conference will be available on the 'investors' section of www.4sc.com.
About Yakult Honsha
Yakult Honsha is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. As for pharmaceutical business Yakult Honsha has an emerging presence in oncology.
For more information on Yakult, visit: http://www.yakult.co.jp/english/index.html or view the following company profile http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf
About 4SC
4SC AG (ISIN DE0005753818) discovers and develops targeted small molecules for autoimmune and cancer indications. Vidofludimus (4SC-101), an IL-17 inhibitor, is currently in Phase II development in rheumatoid arthritis and inflammatory bowel disease (IBD), for which positive results from a Phase IIa study were recently reported. The company's lead oncology compound, resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
Legal Note This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
| Language: | English | |
| Company: | 4SC AG | |
| Am Klopferspitz 19a | ||
| 82152 Martinsried | ||
| Deutschland | ||
| Phone: | +49 (0)89 7007 63-0 | |
| Fax: | +49 (0)89 7007 63-29 | |
| E-mail: | public@4sc.com | |
| Internet: | www.4sc.de | |
| ISIN: | DE0005753818 | |
| WKN: | 575381 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr | |
| in Berlin, Dusseldorf, Munchen, Stuttgart |
No comments:
Post a Comment